Piramal Pharma Solutions invests $32M to expand its riverview Michigan facility

Piramal Pharma Solutions has said it plans to expand its facility in Riverview, Michigan, for which it will invest approximately $32 Million to add capacity and new capabilities in potent and non-potent API development and manufacturing.

This expansion of more than 25,000 square feet, which includes 8,500 square feet of production space, will provide significant benefits to customers and patients, said the company. According to its press release, the capacity will increase in large-scale manufacturing with the addition of new reactors capable of handling up to 4000L.

Peter DeYoung, CEO, Piramal Pharma Solutions said that Piramal Pharma Solutions’ Riverview facility has a well-earned reputation as the preeminent leader in high potency APIs (HPAPIs), and this expansion is designed to ensure that we retain that position. “It enables us to support our customers’ immediate and long-term API needs, strengthens our presence in North America, and enhances our ability to serve patients around the world by delivering the best active ingredients in a timely manner,” he said.

The expansion is planned to be ready for customers beginning Summer 2022. It is expected that the expansion will add approximately twenty new hires to the site, bringing the total headcount to more than 180 employees and further benefitting the local economy, the company said. It added that this would be the seventh major acquisition or expansion by PPS in North America in the past six years demonstrating a sustained substantial commitment to patients, customers, employment, and growth.